Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis

American Journal of Pathology

Volumn 158, Issue 4, 2001, Pages 1423-1432

  Yanagita, Motoko ^a   Arai, Hidenori ^a   Ishii, Kenji ^a   Nakano, Toru ^b   Ohashi, Kazumasa ^c   Mizuno, Kensaku ^c   Varnum, Brian ^e   Fukatsu, Atsushi ^a   Doi, Toshio ^d   Kita, Toru ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; THY 1 ANTIGEN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GLOMERULUS; GROWTH ARREST SPECIFIC GENE 6; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; RAT; RECEPTOR BINDING;

EID: 0035074233     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64093-X     Document Type: Article

References (44)

1. The contribution of glomerular mesangial cells to progressive glomerulosclerosis
2. Evidence for the central role of glomerular growth promoters in the development of sclerosis
3. Mechanisms of progressive renal disease in glomerulonephritis
4. Regulation of mesangial cell proliferation
5. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo
6. Role of platelet-derived growth factor in glomerular disease
7. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats
8. Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1
9. Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis
10. Basic fibroblast growth factor stimulates glomerular mesangial cell proliferation through a protein kinase C-independent pathway
11. Interleukin 6 is an autocrine growth factor for mesangial cells
12. Interleukin-6 exacerbates glomerulonephritis in (NZB × NZW)F1 mice
13. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor
14. Novel approach to specific growth factor inhibition in vivo: Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers
15. SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro
16. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade
17. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases
18. Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors
19. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases
20. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells
21. Roles of gamma-carboxylation and a sex hormone-binding globulin-like domain in receptor-binding and in biological activities of Gas6
22. Mechanism of inhibitory effect of warfarin on mesangial cell proliferation
23. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship
24. Quantitation of mRNA expression in glomeruli using laser-manipulated microdissection and laser pressure catapulting
25. Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis
26. Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis
27. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist
28. Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6
29. GAS6 inhibits granulocyte adhesion to endothelial cells
30. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats
31. Related articles glomerulosclerosis in mice transgenic for growth hormone. Increased mesangial extracellular matrix is correlated with kidney mRNA levels
32. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation
33. Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo
34. N-glycosylation contributes to the intracellular stability of prothrombin precursors in the endoplasmic reticulum
35. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis
36. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial
37. Optimization of inpatient warfarin therapy: Impact of daily consultation by a pharmacist-managed anticoagulation service
38. Warfarin use and fracture risk
39. Drug interactions avoided - A useful indicator of good prescribing practice
40. Management of IgA nephropathy: Evidence-based recommendations
41. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy - Is it relevant for adult patients?
42. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy
43. Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis
44. Dipyridamole and low-dose warfarin without cyclophosphamide in the management of IgA nephropathy